Silence Therapeutics PLC (LON:SLN) has appointed industry veteran Giles Campion as head of research and development and the company’s chief medical officer.
He occupied the same roles at Prosensa, which was acquired by Biomarin in 2015 for US$680mln and, in his 20-year career, he also held senior R&D roles at the Swiss giant Novartis (NYSE:NVS). He holds a medical degree and doctorate from Bristol University.
READ: Silence Therapeutics makes clinical trial application for lead drug
“Giles is a valuable addition to the management team and his expertise will help the company to deliver on its core mission of tackling the unmet medical needs of patients suffering from rare conditions," said Silence chief executive David Horn Solomon.
Campion joins the company on June 1
In a later announcement, Silence also said the search for a permanent chairman continues after announcing that interim chair, Dr Andy Richards, had stepped down with immediate effect.
-- Adds chairman's departure --